CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $) In Thousands, unless otherwise specified	6 Months Ended
	Jun. 30, 2012	Jun. 30, 2011
Cash flows from operating activities:
Net income	$ 47,763	$ 68,529
Adjustments to reconcile net income to net cash (used in) provided by operating activities:
Depreciation and amortization	29,933	28,219
Non-cash interest expense	360	213
Non-cash stock compensation expense	9,467	8,983
Non-cash income tax expense	7,143	6,885
Non-cash amortization on investments	3,720	6,648
Cash flows from changes in assets and liabilities, net of effects from acquisitions of businesses:
Restricted cash	(22,845)	13,697
Accounts receivable, net	1,428	(77,031)
Pharmaceutical inventory	1,213	(17,117)
Other assets	(3,066)	(4,024)
Accounts payable and accrued liabilities	(20,022)	(27,098)
Medical claims payable and other medical liabilities	20,208	(12,390)
Other	(270)	2,598
Net cash (used in) provided by operating activities	75,032	(1,888)
Cash flows from investing activities:
Capital expenditures	(36,877)	(26,693)
Acquisitions and investments in businesses, net of cash acquired		(274)
Purchase of investments	(143,155)	(187,807)
Maturity of investments	150,890	123,043
Net cash used in investing activities	(29,142)	(91,731)
Cash flows from financing activities:
Payments to acquire treasury stock		(211,451)
Proceeds from issuance of equity		20,000
Proceeds from exercise of stock options and warrants	3,003	28,842
Other	(735)	391
Net cash (used in) provided by financing activities	2,268	(162,218)
Net (decrease) increase in cash and cash equivalents	48,158	(255,837)
Cash and cash equivalents at beginning of period	119,862	337,179
Cash and cash equivalents at end of period	$ 168,020	$ 81,342